Malex500 mg+25 mg

Malex is a fixed-dose combination antimalarial (a sulfonamide plus an antifolate) used for:

• Established use: Treatment of acute, uncomplicated malaria caused by Plasmodium falciparum, given as a single dose, particularly in areas where chloroquine resistance is present or suspected.
• Guideline-supported use: Chemoprophylaxis of malaria for travelers to areas with chloroquine-resistant P. falciparum, only when better-tolerated alternatives are unavailable or contraindicated.
• Guideline-supported public health use: Intermittent Preventive Treatment of malaria in pregnancy (IPTp) in malaria-endemic settings, following World Health Organization (WHO) guidance and local antenatal care protocols, using a fixed schedule distinct from standard treatment dosing.

Malex is not effective against chloroquine-sensitive strains alone and is not used for severe or complicated malaria, for which parenteral antimalarials are required.

Each tablet of Sulphadoxine + Pyrimethamine typically contains sulfadoxine 500 mg and pyrimethamine 25 mg (a 20:1 ratio), the combination available in Bangladesh and internationally as an oral tablet.

Malex is a fixed-dose combination of two antifolate antimalarial agents: sulphadoxine, a long-acting sulfonamide, and pyrimethamine, a diaminopyrimidine. Individually each has modest antimalarial activity; together they act synergistically by sequentially blocking two steps of the folate synthesis pathway that the malaria parasite requires for DNA synthesis and replication.

Malex has a long elimination half-life, allowing single-dose treatment regimens and infrequent dosing for prevention, but this combination is now used selectively due to widespread parasite resistance in many regions and the availability of artemisinin-based combination therapies for routine treatment.

Malex belongs to the antimalarial drug class, specifically the antifolate (sulfonamide + dihydrofolate reductase inhibitor) combination subclass.

Mechanism of Action

Sulphadoxine + Pyrimethamine combines two sequential inhibitors of the folate synthesis pathway in the malaria parasite:

• Sulphadoxine competitively inhibits dihydropteroate synthase, blocking incorporation of para-aminobenzoic acid (PABA) into dihydrofolic acid.
• Pyrimethamine selectively inhibits parasitic dihydrofolate reductase, blocking conversion of dihydrofolic acid to the active tetrahydrofolic acid.

Blocking both steps produces a synergistic, sequential blockade that is far more effective than either agent alone and reduces the chance of resistance developing to a single mechanism, though resistance to this combination has emerged in many endemic regions.

Pharmacokinetics

Both components are well absorbed orally, extensively protein-bound, and eliminated slowly (elimination half-lives of roughly 4–11 days for pyrimethamine and 4–9 days for sulphadoxine), which supports single-dose treatment and infrequent prophylactic dosing, with detectable blood levels persisting for several weeks.

Malex tablets are taken orally, swallowed whole (not crushed or chewed unless directed) with a full glass of water or other fluid, preferably after food to minimize stomach upset. For prevention, the first dose should be taken 1–2 days before entering an endemic area, as directed by a physician.

The following interactions with Malex are clinically significant:

• Other antifolate drugs (e.g., trimethoprim, trimethoprim-sulfamethoxazole, other sulfonamides, methotrexate): concurrent use increases the risk of additive antifolate toxicity, including megaloblastic anemia and bone marrow suppression; avoid combining unless specifically directed by a physician.
• Chloroquine: concurrent or closely-timed administration has been associated with an increased risk of adverse reactions, including convulsions; avoid routine co-administration.
• Warfarin and other oral anticoagulants: the sulfonamide component may potentiate anticoagulant effect by displacing warfarin from protein binding; monitor coagulation status if co-administered.
• Lorazepam: reports of increased hepatotoxicity risk with concurrent use.
• Folic acid/folinic acid supplementation: high-dose folate supplementation may reduce antimalarial efficacy, though low-dose routine antenatal folic acid is generally continued under medical guidance during IPTp.

Malex is generally considered compatible with quinine and with antibiotics used as antimalarial adjuncts. Always inform the physician of all medicines being taken before starting Malex.

Most patients receiving single-dose Malex for malaria treatment tolerate it well. Reported adverse effects include:

• Common: nausea, vomiting, loss of appetite, headache, mild skin rash or itching.
• Serious but rare, especially with repeated/prophylactic dosing: severe cutaneous hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be fatal; blood dyscrasias (agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia); hepatic necrosis; erythema multiforme; and, rarely, convulsions or peripheral neuritis.

Malex should be discontinued immediately and medical attention sought at the first sign of skin rash, mucosal lesions, unexplained bruising/bleeding, sore throat, fever, pallor, or jaundice, as these may herald a serious hypersensitivity or hematologic reaction.

Pregnancy: Routine use of Malex for prophylaxis or self-treatment during pregnancy, especially at term, is generally avoided because of a theoretical risk of kernicterus in the newborn from the sulfonamide component, and animal studies have shown teratogenic potential with pyrimethamine at high doses. However, in malaria-endemic regions, the World Health Organization recommends Malex specifically for Intermittent Preventive Treatment in pregnancy (IPTp), starting in the second trimester, as the benefit of preventing malaria-related maternal and fetal complications is judged to outweigh the risks in that specific context. Outside of an IPTp program, Malex should be used in pregnancy only if clearly needed, on a physician's advice, after the potential benefit has been weighed against potential risk to the fetus.

Lactation: Sulfonamides are excreted in breast milk and can theoretically increase the risk of kernicterus in a nursing infant, particularly if the infant is under 2 months of age, premature, jaundiced, or has G6PD deficiency. Malex should be avoided during breastfeeding of such infants; a physician should be consulted before use in any breastfeeding mother.

Serious skin and hypersensitivity reactions: Malex has been associated with rare but potentially fatal reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and other serious sulfonamide-related hypersensitivity reactions such as blood dyscrasias and hepatic necrosis (see Side Effects). Malex must be discontinued immediately and a physician contacted at the first sign of rash or any hypersensitivity symptom; it should generally not be re-administered after such a reaction.

Take exactly as prescribed: Take Malex exactly as prescribed by your physician; do not stop, extend, repeat, skip doses, or share this medicine with others without medical advice, as inappropriate use both increases toxicity risk and contributes to antimalarial drug resistance.

Other precautions:

• Use with caution in patients with impaired renal or hepatic function; periodic monitoring of blood counts and renal/hepatic function is advisable with repeated or prolonged (e.g., prophylactic or IPTp) use.
• Avoid unnecessary sun/UV exposure, as sulfonamides may cause photosensitivity.
• Maintain adequate fluid intake during treatment.
• Not effective for prevention or treatment of malaria caused by chloroquine-sensitive strains where chloroquine alone remains effective, and not appropriate for severe/complicated malaria.
• Use with caution in patients with known allergic or asthmatic conditions.

Overdose of Malex may present with acute symptoms such as nausea, vomiting, headache, dizziness, and central nervous system stimulation including convulsions, followed some days later by folate-deficiency effects such as megaloblastic anemia, leukopenia, thrombocytopenia, and crystalluria.

Suspected overdose is a medical emergency. Seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to treat an overdose at home. Management is supportive and must be carried out by medical professionals, and may include measures to reduce further absorption and specific treatment for folate-deficiency effects, as directed by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Use with caution; avoid repeated/prophylactic dosing of Malex in patients with severe renal impairment (see Contraindications). Dose adjustment or avoidance may be needed even for single-dose treatment in significant renal impairment; consult a physician.

Hepatic impairment: Use with caution; avoid repeated/prophylactic dosing of Malex in patients with severe hepatic impairment (see Contraindications).

Elderly: No specific dose adjustment is established, but elderly patients may be more susceptible to hematologic and hepatic adverse effects; use with caution and monitor accordingly.

G6PD deficiency: Contraindicated (see Contraindications) due to hemolysis risk from the sulfonamide component.

Pediatric and pregnant patients: See Pediatric Uses and Pregnancy and Lactation sections respectively.

For treatment of acute uncomplicated malaria, Malex is given as a single dose (not a multi-day course). For chemoprophylaxis, it is taken weekly or every two weeks for the duration of exposure risk, generally not exceeding 2 years of continuous prophylactic use. For IPTp, dosing is given at scheduled antenatal visits from the second trimester onward, per national protocol, typically at least one month apart.

Antimalarial; antifolate combination (sulfonamide antimalarial + dihydrofolate reductase inhibitor).

Sulphadoxine + Pyrimethamine works by sequential blockade of the folate synthesis pathway in the malaria parasite: sulphadoxine inhibits dihydropteroate synthase, and pyrimethamine inhibits dihydrofolate reductase. Together, they starve the parasite of the folate cofactors needed for DNA synthesis, halting parasite replication.

C

Malex is not recommended for infants younger than 2 months of age due to the risk of kernicterus and immature metabolic pathways; safety and efficacy in this age group have not been established and use is contraindicated.

In children older than 2 months, Malex may be used for single-dose treatment of acute malaria with weight/age-based dosing (see Dosage and Administration), and for chemoprophylaxis on a physician's advice when indicated. Children should be monitored closely for skin reactions and other hypersensitivity symptoms, and the medicine should be stopped immediately if any appear.